12 stories about Generic
מטה חברת טבע תרופות

This Is how Teva and 19 of its Rivals Fixed U.S. Drug Prices

15.05.19|Hezi Sternlicht, Ran Abramson, and Tomer Ganon
A 524-page civil lawsuit filed Friday in the U.S. alleges that 20 generic drugmakers colluded to influence drug prices, with executives meeting regularly to set prices and split the market
מטה טבע פתח תקווה

FDA Approves Teva’s Generic Nasal Spray for Opioid Overdose

21.04.19|Lilach Baumer
Commonly known as Narcan, the spray is considered a life-saving medication, and Teva’s drug is the first generic product approved that does not require medical training to use
מנכ"ל טבע החדש קור שולץ 2

Copaxone Profit will Continue to Fall, But Teva is Set to Double Down on Biosimilars

08.01.19|Lilach Baumer and Hezi Sternlicht
Speaking at J.P. Morgan’s Healthcare Conference on Monday, CEO Kåre Schultz said he expects the U.S. generic market to stabilize in 2019
מטה טבע פתח תקווה

Teva Reaches Confidential Patent Settlement with Neos

The agreement will enable Teva to manufacture and sell a generic version of Neos’ ADHD drug Cotempla as of 2026
תרופה מזרק אפיפן מיילן אלרגיה

Teva, Mylan Drop on Announcement of Epinephrine Injector Rival

09.12.18|Lilach Baumer
Novartis’ U.S. division Sandoz announced a planned release for early 2019. The company will sell its drug, which lacks the EpiPen’s auto-injector, for $250 a pair out of pocket, compared to Mylan and Teva’s $300
מטה טבע פתח תקווה

Teva's Swiss Anti-Nausea Drug Patent Suit Reaches U.S. Supreme Court

05.12.18|Lilach Baumer
Teva was sued in 2011 by Swiss drug company Helsinn Healthcare over its intention to develop a generic version of Helsin's drug, which it released in the U.S. in March 2018
מטה טבע פתח תקווה

Teva, Celltrion Gain FDA Approval for Generic Blood Cancer Bio-Drug

29.11.18|Lilach Baumer
Called Truxima, the drug has been approved to treat several conditions of non-Hodgkin’s lymphoma
אלרגן משרדים

Court Rules Allergan Can't Use Indian Tribe Deal to Protect Patents

In September 2017, Allergan transferred six of its patents for blockbuster dry eye drug Restasis to the St. Regis Mohawk Tribe, hoping to protect the patents under the principle of sovereign immunity
מנכ"ל טבע החדש קור שולץ 2

Teva Increases Junk Senior Note Offering to $4.5 Billion

08.03.18|Lilach Baumer
Last week the debt-laden drugmaker announced a $3.5 billion-equivalent offering to repay its short-term $1.5 billion outstanding debt due July
וורן באפט 2017 ברקשייר האתוויי

Berkshire Hathaway Takes Position in Generic Drugmaker Teva

15.02.18|Lilach Baumer
The holding company disclosed a $358 million stake in the struggling company
מנכ"ל AstraZeneca פסקל סוריו Pascal Soriot

Teva in Talks to Appoint AstraZenca's Pascal Soriot as CEO

18.07.17|Golan Hazani
Mr. Soriot has met with the company’s search committee and its chairman and expressed his agreement to serve as its next CEO, people familiar with the matter said